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Abstract
Background: Patients with Congenital Hyperinsulinism (CHI) due to mutations in K-ATP channel genes (K-ATP CHI) are
increasingly treated by conservative medical therapy without pancreatic surgery. However, the natural history of
medically treated K-ATP CHI has not been described; it is unclear if the severity of recessively and dominantly inherited
K-ATP CHI reduces over time. We aimed to review variation in severity and outcomes in patients with K-ATP CHI
treated by medical therapy.
Methods: Twenty-one consecutively presenting patients with K-ATP CHI with dominantly and recessively inherited
mutations in ABCC8/KCNJ11 were selected in a specialised CHI treatment centre to review treatment outcomes. Medical
treatment included diazoxide and somatostatin receptor agonists (SSRA), octreotide and somatuline autogel. CHI
severity was assessed by glucose infusion rate (GIR), medication dosage and tendency to resolution. CHI outcome was
assessed by glycaemic profile, fasting tolerance and neurodevelopment.
Results: CHI presenting at median (range) age 1 (1, 240) days resolved in 15 (71%) patients at age 3.1(0.2, 13.0) years.
Resolution was achieved both in patients responsive to diazoxide (n = 8, 57%) and patients responsive to SSRA (n = 7,
100%) with earlier resolution in the former [1.6 (0.2, 13.0) v 5.9 (1.6, 9.0) years, p = 0.08]. In 6 patients remaining on
treatment, diazoxide dose was reduced in follow up [10.0 (8.5, 15.0) to 5.4 (0.5, 10.8) mg/kg/day, p = 0.003]. GIR at
presentation did not correlate with resolved or persistent CHI [14.9 (10.0, 18.5) v 16.5 (13.0, 20.0) mg/kg/min, p = 0.6].
The type of gene mutation did not predict persistence; resolution could be achieved in recessively-inherited CHI with
homozygous (n = 3), compound heterozygous (n = 2) and paternal mutations causing focal CHI (n = 2). Mild
developmental delay was present in 8 (38%) patients; adaptive functioning assessed by Vineland Adaptive Behavior
Scales questionnaire showed a trend towards higher standard deviation scores (SDS) in resolved than persistent CHI
[−0.1 (−1.2, 1.6) v −1.2 (−1.7, 0.03), p = 0.1].
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Conclusions: In K-ATP CHI patients managed by medical treatment only, severity is reduced over time in the majority,
including those with compound heterozygous and homozygous mutations in ABCC8/KCNJ11. Severity and treatment
requirement should be assessed periodically in all children with K-ATP CHI on medical therapy.
Keywords: Hypoglycaemia, Congenital hyperinsulinism, Insulin, Genetics, Mutations, Diazoxide, Octreotide,
Neurodevelopment
Background
Congenital Hyperinsulinism in Infancy (CHI) is a rare
disorder causing severe debilitating hypoglycaemia, usu-
ally presenting in infancy [1, 2]. Hypoglycaemia due to
CHI can have a deleterious impact on early life brain
function, with several cohorts reporting adverse neuro-
developmental outcomes in a third to a half of patients
[3–6]. The frequency of hypoglycaemia-related brain in-
jury in the CHI population as a whole has not reduced
despite optimisation of diagnosis and treatment over the
last decade. The burden of morbidity in CHI continues
to be a major problem for individuals and health care
professionals; therefore, a greater focus is required on
understanding variations in disease severity.
Genetic understanding of CHI has progressed rapidly
with a significant proportion of CHI found to have under-
lying genetic causes, most frequently mutations in the K-
ATP channel genes, ABCC8 and KCNJ11 [7, 8]. K-ATP
channel genotyping has stratified treatment protocols of
focal and diffuse CHI with paternal heterozygosity most
commonly associating with focal CHI and maternal
heterozygous, homozygous or compound heterozygous
mutations in ABCC8/KCNJ11 associating with diffuse dis-
ease [2]. Although paternal heterozygosity has a higher
predilection for focal CHI, additional investigation such as
18-fluoro-dopa PET-CT scanning is necessary to localise
the lesion in focal CHI; a significant proportion, as many
as half with paternal heterozygous mutations in some re-
ports may have diffuse CHI [9] which could be explained
by dominant inheritance or inability to identify a maternal
mutation in recessively-inherited disease.
It is recognised that pancreatectomy, either lesionect-
omy for focal lesions or subtotal pancreatectomy for
severe diffuse CHI is a well-established treatment choice
for CHI. However, increasingly there is a shift to conserva-
tive medical management particularly in the case of dif-
fuse CHI which is traditionally treated by near total
pancreatectomy. Indeed, some children with focal CHI in
the head of the pancreas proximal or abutting the bile
duct may benefit from conservative treatment due to the
nature of the surgical complexity involved. In our centre,
the frequency of patients (with K-ATP and non-K-ATP
channel gene mutations) undergoing pancreatic surgery as
a proportion of new patients referred to the service has re-
duced from 18% in 2007–2008 to 6–7% in 2014–2015.
A number of case reports of spontaneous resolution of
disease have been reported [10–12], mostly in those
without known genetic mutations, while cohort studies
in different countries have characterised surgical
outcomes only [4, 7, 8, 13]. Long-term conservative
treatment with diazoxide and octreotide without re-
quirement for pancreatic surgery has also been reported
in patients with and without K-ATP channel gene mutations
[12, 14, 15]; however these observations do not offer insight
into the evolution of disease severity and if treatment re-
sponse improves or worsens over time. Therefore, disease
trajectories of medically treated K-ATP CHI remain poorly
understood. It is important to understand the trends in se-
verity of CHI to modify and individualise the intensity of
medical therapy. Here we have studied a cohort of patients
with K-ATP CHI treated by medical therapy to examine
outcomes of disease in follow up assessments.
Methods
The aims of our study were to assess variation in inten-
sity of treatment in children with K-ATP CHI over time,
and to review outcomes of medically treated K-ATP CHI
patients in follow up assessments.
A cohort of patients with K-ATP CHI (mutations in
ABCC8/KCNJ11) treated by medical therapy (n = 21)
was identified from a group of patients (n = 404) in a
specialist centre for CHI between April 2006 and July
2016, with local Research Ethics approval. Genetic inves-
tigations were performed in 269 patients only within the
cohort. In the remainder, genetic investigations were not
performed because CHI resolved in early infancy or pa-
tients remained on low dose diazoxide. In those under-
going genetic testing, 71 patients had mutations in
ABCC8/KCNJ11, 10 patients had mutations in other
genes related to CHI (HNF4A, GCK, HADH, GLUD1)
and 10 patients had variants of uncertain clinical signifi-
cance. Within the group of 71 patients with ABCC8/
KCNJ11 mutations, 39 patients underwent pancreatic
surgical treatment (subtotal pancreatectomy or focal
lesionectomy); patients who were not surgically treated,
Salomon-Estebanez et al. Orphanet Journal of Rare Diseases  (2016) 11:163 Page 2 of 11
i.e. medically treated (n = 21) were recruited to the study.
Eleven patients who were also medically treated were
not recruited because they either presented between
January 2016 and July 2016, or insufficient clinical infor-
mation was available in follow up.
The diagnosis of CHI was made in patients presenting
to this centre using well-established criteria [1, 2]. Pa-
tients underwent rapid K-ATP channel gene mutation
analysis as per protocol, as previously reported [10]. Var-
iants either previously reported or considered likely to
be pathogenic were included in the cohort. One variant
reported as pathogenic in our patient but classified else-
where as being a variant of uncertain significance was
also included.
The diagnosis of focal CHI was made on the basis of a
paternal heterozygous mutation in ABCC8/KCNJ11 and
confirmed by identification of a solitary lesion in the
pancreas during 18-fluoro-dopa PET-CT scanning [2].
Those with no clear foci were diagnosed as diffuse CHI.
Diffuse CHI was also presumed if the patient had
maternal heterozygous, homozygous, or compound het-
erozygous mutations in ABCC8/KCNJ11, for which 18-
fluoro-dopa PET-CT scans were not performed. Patients
with ABCC8/KCNJ11 mutations who required either
lesionectomy for focal CHI or subtotal pancreatectomy
for diffuse CHI were excluded from the cohort. Patients
who underwent pancreatic biopsy or minimal resection
while continuing medical therapy were included in the
cohort.
Treatment variations were made on clinical grounds
and individualised to patient need. Oral diazoxide was
used as first line treatment, while somatostatin agonists
(SSRA, octreotide, somatuline) were used as second line
treatment. Carbohydrate supplements to increase energy
content of milk and polyunsaturated fatty acids (PUFA)
used in the management of diazoxide responsive CHI
were considered as food supplements and did not pre-
clude inclusion to the cohort [16]. The dose of
Eicosapentaenoic acid (EPA) component of omega-3
fatty acid was allowed in a range of 240–480 mg per day.
Responsiveness to diazoxide as treatment for CHI was
determined by noting satisfactory glucose profiling and
fasting tolerance as described previously [16]. Respon-
siveness to SSRA was also determined in a similar
manner.
Children had resolution of CHI if treatment was mini-
mised and withdrawn completely with maintenance of
satisfactory glucose profiles (95% values >3.5 mmol/L)
on home glucose monitoring or subcutaneous continu-
ous glucose monitoring (CGM) [10, 16]. To achieve
resolution of CHI, satisfactory fasting tolerance was
mandatory with end of fast blood glucose >3.0 mmol/L,
suppressed insulin concentrations and blood ketones
>1.0 mmol/L measured by point of care testing and/or
laboratory analysis of 3 hydroxybutyrate. Follow-up con-
sisted of telephone reviews every 2 weeks for the first
4 months, followed by clinic reviews at 4 monthly inter-
vals by a multi-disciplinary team including a clinician,
two specialist nurse practitioners, two dietitians, a
speech and language therapist and a clinical psycholo-
gist. At each review, glucose profile was assessed and
medication adjusted accordingly. Children who demon-
strated resolution of CHI were reviewed in clinic ap-
pointments every 6 months by a clinician and specialist
nurse practitioner without wider multi-disciplinary team
input. Annual home blood glucose profiles were assessed
to determine glycaemic status and to ensure continuing
euglycaemia. Oral glucose tolerance testing was not per-
formed routinely in all children undergoing spontaneous
resolution, in the absence of information regarding long-
term utility and difficulty in administering the test in
young children. Instead, home blood glucose profiling was
assessed and correlated with symptoms of hypoglycaemia
and hyperglycaemia. Pancreatic biopsy was not routinely
undertaken in patients enrolled in the cohort. However,
for patients in whom a pancreatic biopsy was undertaken
as a partial resection, the tissue was analysed for charac-
teristics of focal and diffuse CHI [17].
In addition to glycaemic outcomes in follow up assess-
ment, the Vineland Adaptive Behavior Scales, version II
(VABS-II), a questionnaire completed by parents was
used to assess adaptive functioning in the domains of
communication, daily living skills, social skills and motor
skills after age 1.5 years (http://www.pearsonclinical.com/).
Information was also obtained on the prevalence of seizures
and delayed development in clinical assessment [3].
Auxology parameters were reviewed at the 2 year
follow up assessment and measurements were converted
to Standard Deviation Scores (SDS) [18]. Statistical ana-
lysis was performed by IBM-SPSS version 23.0 (IBM in-
corporated, New York, USA); Mann–Whitney test was
performed to test differences between non-parametric
independent variables while paired t-tests were used to
test difference between paired samples.
Results
Patient characteristics
Twenty-one patients presented with hypoglycaemia at a
median age (range) 1 day(1 day, 8 months) with glucose
1.7(0.1, 2.6) mmol/L, insulin 97.2(16.8, 234.0) pmol/L
and glucose infusion rate 14.9(10.0, 20.0) mg/kg/min.
Birth weight SDS was 2.0(−0.5, +3.8), with weight SDS
and height SDS at age 2 years being +1.7(−1.4, +3.8) and
+1.0(−2.0, +2.2) respectively. Information on age at pres-
entation, focal and diffuse CHI, medication, feeding and
neurodevelopment has been provided in Table 1 with
gene mutation status provided in Table 2.
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#1 5.3 Neonate 2.6 Diffuse Compound
heterozygous ABCC8
DZX 5 mg/kg/d 0 Orally Speech delay
#2 9.3 Neonate 3.5 Diffuse Maternal KCNJ11 DZX 10 mg/kg/d 0 Gastrostomy (4 years) Speech delay
#3 16.6 Neonate 13 Diffuse de novo ABCC8 DZX 7 mg/kg/d 0 Orally Normal
#4 9.4 Neonate 0.7 Diffuse Maternal ABCC8 DZX 9.2 mg/kg/d 0 Orally Seizures at presentation,
behavioural problems
#5 4.3 Neonate 3.1 Diffuse Maternal ABCC8 DZX 7.1 mg/kg/d 0 Orally Normal
#6 0.7 Neonate 0.4 Diffuse Paternal ABCC8 DZX 5 mg/kg/d 0 Orally Normal
#7 6.7 Day 2 0.5 Diffuse Maternal ABCC8 DZX 5 mg/kg/d 0 Orally Epilepsy, motor delay,
coordination problems
#8 2.7 Day 2 0.2 Diffuse Maternal ABCC8 DZX 5 mg/kg/d 0 Orally Normal
#9 7.2 Day 1 6 Diffuse Homozygous ABCC8 OCT 18.5 mcg/kg/d;
Somatuline 60 mg
4-7 weekly
0 Gastrostomy (2.5 years) Normal
#10 2.7 Day 1 1.6 Focal Paternal KCNJ11 OCT 15 mcg/kg/d 0 Gastrostomy (1.3 years) Normal
#11 10.9 8 months 6.6 Focal Paternal ABCC8 OCT 19 mcg/kg/d 0 Orally Normal
#12 7.1 Day 1 7 Diffuse Compound
heterozygous ABCC8
OCT 14.5 mcg/kg/d 0 Gastrostomy (3.6 years) Normal
#13 5.7 Day 1 1.9 Diffuse Paternal KCNJ11 OCT 3.8 mcg/kg/d 0 Gastrostomy (1.7 years) Normal
#14 12.3 Day 1 9 Diffuse Homozygous ABCC8 OCT 19.2 mcg/kg/d 0 Gastrostomy (1.2 years) Mild gross motor,
speech delay
#15 7.6 Day 70 5.5 Diffuse Presumed paternal
KCNJ11
OCT 17 mcg/kg/d 0 Gastrostomy (2.0 years) Normal
#16 8.9 Day 5 Not
resolved
Diffuse Paternal KCNJ11 DZX 10 mg/kg/d DZX 6 mg/kg/d Orally Epilepsy, speech, motor, l
earning difficulties
#17 1.1 Day1 Not
resolved
Diffuse Homozygous ABCC8 DZX 10 mg/kg/d DZX 0.5 mg/kg/d Orally Normal
#18 1.3 Day 2 Not
resolved
Diffuse Paternal KCNJ11 DZX 8.5 mg/kg/d DZX 5.8 mg/kg/d Orally Normal
#19 5.1 Neonate Not
resolved
Diffuse de novo ABCC8 DZX 15 mg/kg/d DZX 10.8 mg/kg/d Gastrostomy (continuing at
present)
Normal
#20 6.8 Day 2 Not
resolved
Diffuse Maternal ABCC8 DZX 9.6 mg/kg/d DZX 3.1 mg/kg/d Orally Epilepsy, motor delay,
behavioural problems
#21 3.2 Day 1 Not
resolved
Diffuse Paternal KCNJ11 DZX 12.5 mg/kg/d DZX 5 mg/kg/d Gastrostomy (overnight only,
continuing)
Speech delay
Patient characteristics in this cohort of patients with medically treated K-ATP CHI (n = 21), showing age at presentation, resolution status, diffuse/focal, medication dosage (DZX - diazoxide, OCT - octreotide), feeding















Table 2 Genetic characterisation of patients with medically treated K-ATP CHI









Deletion is novel, A355T reported
in Ismail (2010) [24], Russo (2011) [25],
Snider (2013) [8], Mohnike (2014) [26]
#2 Missense KCNJ11
p.T294M (c.881C>T)
Arya (2014) [9], Shimomura (2009) [27],
Bellanne-Chantelot (2010) [28], Ilmaran
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Genetic characterisation of patients with medically treated K-ATP CHI, showing gene defect, protein changes, type of mutation, mode of inheritance and citations
(see references). *The p.G40D mutation is presumed to be of paternal origin. The mutation was not present in the sample from the mother and the father was
unavailable for testing. The mutation in patient #16 has been classified in other publications as a variant of uncertain significance
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Recessively acting mutations were identified in 7
(33%) patients; 3 patients had homozygous mutations,
2 patients had compound heterozygous mutations in
ABCC8 and 2 patients had focal CHI (one paternally
inherited mutation in ABCC8 and one paternally
inherited mutation in KCNJ11). A single heterozygous
mutation was identified in 14 (67%) patients; 5 pa-
tients had maternally inherited ABCC8 mutations, 2
patients had de novo ABCC8 mutations (no mutations
identified in parents), 1 patient had a paternally
inherited ABCC8 mutation without focal CHI, 5 pa-
tients had paternally inherited KCNJ11 mutations
without focal CHI and 1 patient had a maternally
inherited KCNJ11 mutation.
Case illustrations
1. Patient #9 with a homozygous ABCC8 mutation
and severe CHI at presentation was unresponsive
to diazoxide. He was treated with octreotide via
subcutaneous pump to a maximum dose of 18.5
mcg/kg/day and then switched to somatuline
autogel 60 mg every 4 weeks subcutaneously.
Monitoring at home showed normal glucose
profiles, prompting somatuline injection intervals
to be gradually increased from 4 to 7 weeks without
recurrence of hypoglycaemia. However, the patient
became increasingly intolerant of needles and injections,
at which point his parents requested a trial period
without medical therapy, adding PUFA as a food
supplement and monitoring carefully for relapse into
hypoglycaemia. One year after stopping somatuline, this
patient remains on PUFA as a food supplement in a
dose 260 mg twice a day with satisfactory fasting
tolerance, normal food frequency and regular daily
activity including school.
2. Patient #10 with a previously reported paternal
KCNJ11 missense mutation and 18- fluoro-dopa
PET-CT scanning suggesting a lesion in the tail
also had severe CHI at presentation. In the pre-
operative period, euglycaemia was achieved with
a combination of octreotide in a dose of 15 mcg/
kg/day and gastrostomy feeding. At laparoscopic
surgery, the lesion was not identified at the ana-
tomical location suggested by imaging investiga-
tions. Her pancreatic tail biopsy showed normal
histology, implying the presence of focal CHI else-
where in the pancreas. Following discussion with
parents, she was medically-treated with octreotide.
In follow up, octreotide was gradually decreased
and then stopped at age 1.6 years with satisfac-
tory fast tolerance and normal glucose profiles,
which persists after 1.1 years of treatment
withdrawal.
Variation in natural history: tendency to resolution
Fourteen patients (67%) received diazoxide treatment
with good treatment response. Seven (33%) patients re-
ceived SSRA treatment because they were either unre-
sponsive or partially responsive to diazoxide (n = 6) or
developed adverse reactions to diazoxide (n = 1). In fol-
low up assessments, diazoxide dose was reduced in all
patients [8.8(5.0, 15.0) to 0.0(0.0, 10.8) mg/kg/day (p <
0.001 for difference)] (Fig. 1). Eight patients on diazoxide
achieved resolution after a period of 1.6(0.2, 13.0) years.
Six patients on diazoxide did not achieve resolution and
remained on treatment, although dose was reduced sig-
nificantly [10.0 (8.5, 15.0) to 5.4 (0.5, 10.8) mg/kg/day, p
= 0.003] after a period of 4.1 (1.1, 8.9) years. In 7 pa-
tients who received SSRA treatment [maximum octreo-
tide dose 17.0(3.8, 19.2) mcg/kg/day], resolution was
achieved in all. Resolution following SSRA treatment
was noted in 2 patients (patients #11 and #15) who pre-
sented beyond the neonatal period. Patient #15 had dif-
fuse CHI and was responsive to SSRA treatment, which
was preferred in favour of sub-total pancreatectomy. In
contrast, the diagnosis of focal CHI in patient #11 was
delayed as initial genetic screening by Sanger sequencing
of ABCC8 exons did not find a mutation. The paternal
ABCC8 mutation (Table 2) was later identified as a
splice site mutation, with focal CHI being confirmed by
18-fluoro-dopa PET-CT scanning. While focal lesionect-
omy was being planned, the patient’s medical manage-
ment was reviewed; SSRA was stopped with satisfactory
glucose measurements on a profile and a fast.
Resolution tended to be later in those receiving SSRA
than in those receiving diazoxide [5.9(1.6, 9.0) v 1.6(0.2,
13.0) years of treatment, p = 0.08]. Overall, CHI resolved
in 15 (71%) children in this cohort at age 3.1 (0.2, 13.0)
years with age appropriate fasts in hospital (16–20 h)
demonstrating absence of hypoglycaemia, suppressed in-
sulin secretion and robust ketotic responses (Additional
file 1: Figure S1 and Additional file 2: Figure S2) sup-
ported by satisfactory home glucose monitoring.
Factors associating with severity of illness were investi-
gated for association with CHI resolution. GIR, a marker
of severity of hypoglycaemia at presentation, was mar-
ginally less in resolved CHI than in persistent CHI pa-
tients [14.9(10.0, 18.5) v 16.5(13.0, 20.0) mg/kg/min, p =
0.6]. Maximum diazoxide dose was also significantly less
in resolved CHI than in persistent CHI patients [6.0(5.0,
10.0) v 10.0(8.5, 15.0), p = 0.04]. Similar analysis was not
performed in those on SSA, as resolution was achieved
in all children.
Neurodevelopmental outcomes
Mild delayed development was observed in 8 (38%) chil-
dren in one or more domains (Table 1). The proportion
of children having developmental delay was not
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significantly different between those with resolved CHI
and persistent CHI [5(33%) v 3(50%), p = 0.5] and be-
tween those feeding orally and those requiring gastros-
tomy tube feeding [5(42%) v 3(33%), p = 0.7]. GIR was
similar between those with and without developmental
delay [15.7(13.0, 18.5) v 14.9(10.0, 20.0), p = 0.8]. Patients
#9 and #17 with homozygous mutations and #12 with a
compound heterozygous mutation had normal develop-
mental outcomes. However patient #14 who had a
homozygous mutation had mild motor and speech delay.
VABS-II scores were available in 12 (57%) children
older than 1.5 years of age (Fig. 2). VABS-II scores were
within an acceptable population range at 0.3(−1.7, +1.6)
SDS, with trend towards higher scores (better adaptive
functioning) in resolved compared with persistent CHI
[−0.1(−1.2, +1.6) v −1.2(−1.7, +0.1), p = 0.1] for most do-
mains, but not reaching significance. Out of the VABS-II
domains, daily living skills showed a significant
difference with higher scores, i.e. a more favourable de-
velopmental outcome in resolved CHI compared to
those with persistent CHI [−0.2 (−1.4, +0.6) v −1.6 (−2.0,
−0.6), p = 0.02].
Feeding outcomes
Twelve (57%) children were fed orally without require-
ment for nasogastric or gastrostomy tube feeding
(Table 1). In those with oral food refusal and aversion,
gastrostomy tube feeding continued in part or full for a
variable period ranging between 1.3 and 5.1 years. Re-
solved CHI was similar in frequency between orally feed-
ing and gastrostomy feeding children [8(67%) v 7(78%),
p = 0.6]. Abnormal development was also similar in fre-
quency between orally- and gastrostomy-fed children
[5(42%) v 3(33%), p = 0.7].
Discussion
Our study of young patients with K-ATP CHI suggests
that resolution of CHI occurs in a significant proportion
(71%) of those safely managed by conservative medical
treatment. Resolution may not occur in all patients in
prolonged follow up, but there is reduction in the inten-
sity of treatment for hypoglycaemia, suggesting a trend
of reducing severity of disease over time.
Our findings of reducing severity in both recessively or
dominantly inherited ABCC8/KCNJ11 mutations extend
the recognised theme that dominant mutations may be
mild [19] and that resolution can occur in a few children
with recessively inherited disease [11, 20]. This notion is
also commensurate with observations in large cohorts
where patients with homozygous and compound hetero-
zygous mutations may be medically managed without
need for pancreatic surgery [7]. While it is recognised
that the natural history of CHI may become clinically
more manageable, our report provides objective and sys-
tematic evidence for this prevailing notion. Our findings
also provide much needed prognostic information about
Fig. 1 Maximum and present doses of diazoxide in children with CHI represented as box and whisker plots (median, 95% confidence intervals). In
persistent CHI (CHI-Persistent), a higher maximal dose of diazoxide was required than in patients with resolved CHI (CHI-Resolved). Diazoxide dose
was reduced both in CHI-Resolved and CHI-Persistent groups of patients
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the disease trajectory of K-ATP CHI and guidance for
clinicians to re-evaluate severity at successive intervals
and reduce medication as necessary.
We accept that patient numbers are relatively small
and that only five patients with compound heterozygous
and homozygous mutations represented severe diffuse
medically treated CHI. However, patient numbers are
not small for a rare disease drawn from a relatively large
group of patients with genetic and non-genetic CHI over
a 10 year period. Nonetheless, replication in other inter-
national cohorts would be helpful to prove the strength
of association. Larger cohorts and international data-
bases would be required to determine factors associated
with reduction in severity as the number of patients in
our cohort were too few (n = 7) to hypothesise mecha-
nisms of disease resolution in CHI caused by recessively
inherited mutations.
Only six children in this cohort remained on long-
term medication. Two of these patients had missense
mutations affecting KCNJ11 residue p.R206. Three other
patients tested in Exeter had mutations at this residue
and had congenital hyperinsulinism that persisted for
between 21 months and >3 years. The ABCC8 p.R526C
mutation was reported in a patient who required treat-
ment up to the age of 6 years [21]. However, a genoty-
pe:phenotype correlation is not absolute since the
ABCC8 p.I1512T mutation was found in another patient
tested in Exeter whose hyperinsulinism remitted within
a few days of birth.
In our study, we have provided genetic information on
the type of K-ATP channel gene mutations in CHI
patients. However, we have not investigated genotype
predictions of natural history phenotype as in-silico pre-
dictions are unreliable in establishing pathogenicity and
have not been tested in model predictions of disease tra-
jectory. As experience in medical management of pa-
tients with K-ATP CHI accumulates worldwide, our
study suggests the need to generate phenome databases
to derive genotype-assisted prediction models of disease
prognosis.
Although patients in our cohort had reducing sever-
ity, the neurodevelopmental phenotype was no differ-
ent to previous cohorts [3, 5, 6]. This is likely to
reflect adverse impact of hypoglycaemia in early life
[3] and not likely to reflect the impact of continuing
hypoglycaemia, as home glucose monitoring had been
satisfactory in all patients. Further strength comes
from the observation that the majority of the most
severe patients, i.e. those with homozygous and com-
pound heterozygous mutations had normal neurode-
velopmental outcomes.
We did not observe deterioration in oral feeding with
treatment reduction and disease resolution. The majority
of children in this cohort were orally fed; those requiring
gastrostomy tube feeding improved oral feeding over
time. Therefore, treatment withdrawal or reduction was
not associated with the collateral effect of increasing re-
liance on gastrostomy tube feeding.
Fig. 2 Vineland Adaptive Behavior Scales, 2nd edition (VABS-II) scores as standard deviation scores (SDS) for patients with persistent CHI (CHI-
Persistent) and resolved CHI (CHI-Resolved), represented as box and whisker plots (median, 95% confidence intervals). Total SDS scores
representing the Adaptive Behavior Composite (ABC) are shown in white boxes while individual domains are depicted in colour
Salomon-Estebanez et al. Orphanet Journal of Rare Diseases  (2016) 11:163 Page 8 of 11
Although we have reported a reduction in disease se-
verity in the natural history and progression of genetic
forms of CHI, we have been unable to find markers at
presentation that could predict the resolution of disease.
Therefore, it follows that CHI should be treated aggres-
sively at the outset as recommended [1, 22], but with
regular monitoring in follow-up to reduce treatment
dosage, where feasible. The reduction in treatment in-
tensity is not only a responsive management strategy,
but also potentially reduces the significant harm to pa-
tients from excessive doses and prolonged exposure to
medications with recognised toxic adverse effect profiles.
We would recommend telephone and/or electronic
communication every 2 weeks for the first 4 months to
understand trends in home glucose profiles and drug re-
sponse, followed by 4 monthly clinic reviews to assess
the need for dose reduction. We would also suggest an-
nual review of therapy for those remaining on treatment
for longer than a year. Although we did not find patients
experiencing relapse of hypoglycaemia in the relatively
short duration of follow up, we would suggest on-going
monitoring for the risk of hypoglycaemia, particularly
during illness episodes for at least 2 years.
One criticism to adopt a step down treatment approach
is the exposure to the potential risk of hypoglycaemia.
However, the frequency of adverse neurodevelopment in
our cohort was no different in those between resolution
and persistence of CHI and no different than previous co-
horts [5, 6]. The frequency of adverse neurodevelopment
in the medically treated group has not been compared dir-
ectly with the frequency in patients treated surgically in
our cohort, although comparison of our data with other
cohorts suggests a similar prevalence [4]. If early onset
hypoglycaemia is the most important determinant of later
life adverse neurodevelopment [3], it is unlikely that the
small risk of hypoglycaemia from a proposed reduction in
therapeutic intensity would be more detrimental. None-
theless, it would be advisable to weigh up risks and bene-
fits when offering treatment de-escalation choices to
parents of children with CHI.
In our study of natural history outcomes, we did not
evaluate glucose tolerance as part of the assessment of
glycaemic outcomes, unlike other studies following pan-
createctomy [23]. However, the utility of glucose toler-
ance testing at a young age in patients with resolving
CHI not requiring surgery has not been established.
Nonetheless, it would be important to evaluate formal
glucose tolerance in older children and adolescents with
resolved CHI to investigate the probability of evolving
hyperglycaemia and diabetes.
Conclusions
A reduction in severity of CHI was noted in all patients
with K-ATP CHI, while a significant majority achieved
hypoglycaemia resolution in follow up assessment, in-
cluding those with compound heterozygous and homo-
zygous mutations. Information about reducing severity
could be discussed early in the management of CHI to
guide prognosis and parental expectations. In children
who are medically managed, disease severity should be
periodically reviewed to assess the need to reduce medi-
cation dosage in anticipation of disease resolution.
Additional files
Additional file 1: Figure S1. Mean blood glucose levels (95%
confidence intervals) before and after prolonged fasting in patients with
resolved CHI. (BMP 919 kb)
Additional file 2: Figure S2. Mean blood ketone (3 hydroxybutyrate)
levels (95% confidence intervals) before and after prolonged fasting in
patients with resolved CHI. (BMP 919 kb)
Abbreviations
CGM: Continuous glucose monitoring; CHI: Congenital hyperinsulinism;
EPA: Eicosapentaenoic acid; GIR: Glucose infusion rate; K-ATP CHI: Congenital
hyperinsulinism due to mutations in K-ATP channel genes;
PUFA: Polyunsaturated fatty acids; SDS: Standard Deviation Scores;
SSRA: Somatostatin receptor agonists; VABS-II: Vineland Adaptive Behavior
Scales, version II
Acknowledgements
The authors are grateful to research nurses and clinical colleagues at Central
Manchester University Hospitals NHS Trust and the Manchester Biomedical
Research Centre.
Funding
The study received funding from the following sources: National Institute for
Health Research, Translational Research Collaboration, NORCHI Charitable
Fund, Research and Innovation supporting funds from Central Manchester
University Hospitals and University of Manchester and The Million Dollar Bike
Fund. SEF has a Sir Henry Dale Fellowship jointly funded by the Wellcome
Trust and the Royal Society (Grant Number: 105636/Z/14/Z). KEC was funded
by a Research Councils UK Academic Fellowship.
Availability of data and material
All data generated or analysed during this study are included in this
published article in the format uploaded.
Authors’ contributions
MSE, SEF, MJD, KEC, JN, IB authored the manuscript. IB, MSE and MJD were
responsible for design and methods. SE, LR, LB, ZM, MS, CH, RC, RP, NM and
TR were involved in data collection, analysis and critical comments on the
writing of the manuscript. MSE and IB were responsible for statistical analysis.
All authors read and approved the final manuscript.
Authors’ information
Dr Salomon-Estebanez is a clinical research fellow in Congenital Hyperinsuin-
ism at the Northern Congenital Hyperinsulinism (NORCHI) service in the
Royal Manchester Children’s Hospital and University of Manchester.
Professor Mark Dunne and Dr Karen Cosgrove are research scientists at the
Faculty of Biology, Medicine and Health in the University of Manchester.
Professor Sian Ellard is based at the Human Molecular Genetics at the
University of Exeter Medical School. She is also a Consultant Clinical Scientist
at the Royal Devon and Exeter NHS Foundation Trust where she heads the
Molecular Genetics Department.
Dr Sarah Flanagan is a Henry Dale Research Fellow at the University of Exeter
Medical School.
Dr Indraneel Banerjee is a consultant paediatric endocrinologist at the Royal
Manchester Children’s Hospital and Faculty of Biology, Medicine and Health
at the University of Manchester.
Salomon-Estebanez et al. Orphanet Journal of Rare Diseases  (2016) 11:163 Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable (no individual patient information disclosed).
Ethics approval and consent to participate
This study was supported the The North West Research Ethics Committee
(project reference number: 07/H1010/88) to which parents were consented
to participate.
Author details
1Department of Paediatric Endocrinology, Royal Manchester Children’s
Hospital, Central Manchester University Hospitals, Oxford Road, Manchester
M13 9WL, UK. 2Institute of Biomedical and Clinical Science, University of
Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road,
Exeter EX2 5DW, UK. 3Department of Paediatric Endocrinology and Diabetes,
Nottingham Children’s Hospital, Nottingham University Hospitals, Derby
Road, Nottingham NG7 2UH, UK. 4Paediatric Psychosocial Department, Royal
Manchester Children’s Hospital, Central Manchester University Hospitals,
Oxford Road, Manchester M13 9WL, UK. 5Therapy and Dietetic Department,
Royal Manchester Children’s Hospital, Central Manchester University
Hospitals, Oxford Road, Manchester M13 9WL, UK. 6Department of Paediatric
Surgery, Royal Manchester Children’s Hospital, Central Manchester University
Hospitals, Oxford Road, Manchester M13 9WL, UK. 7Department of Diabetes
and Endocrinology, Children’s University Hospital, Temple Street, Dublin,
Ireland. 8Faculty of Biology, Medicine and Health, University of Manchester,
Oxford Rd, Manchester M13 9PL, UK.
Received: 20 August 2016 Accepted: 22 November 2016
References
1. Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A,
Valayannopoulos V, Brunelle F, Fournet JC, Robert JJ, Aigrain Y, et al.
Congenital hyperinsulinism: current trends in diagnosis and therapy.
Orphanet J Rare Dis. 2011;6:63.
2. Banerjee I, Avatapalle B, Padidela R, Stevens A, Cosgrove K, Clayton P,
Dunne M. Integrating genetic and imaging investigations into the clinical
management of congenital hyperinsulinism. Clin Endocrinol (Oxf). 2013;
78(6):803–13.
3. Avatapalle HB, Banerjee I, Shah S, Pryce M, Nicholson J, Rigby L, Caine L,
Didi M, Skae M, Ehtisham S, et al. Abnormal neurodevelopmental outcomes
are common in children with transient congenital hyperinsulinism. Front
Endocrinol (Lausanne). 2013;4:60.
4. Lord K, Radcliffe J, Gallagher PR, Adzick NS, Stanley CA, De Leon DD. High
risk of diabetes and neurobehavioral deficits in individuals with surgically
treated hyperinsulinism. J Clin Endocrinol Metab. 2015;100(11):4133–9.
5. Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E. Long-term
follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol.
2003;149(1):43–51.
6. Menni F, de Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, Nihoul-Fekete
C, Saudubray JM, Robert JJ. Neurologic outcomes of 90 neonates and
infants with persistent hyperinsulinemic hypoglycemia. Pediatrics. 2001;
107(3):476–9.
7. Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K. Clinical and
molecular characterisation of 300 patients with congenital hyperinsulinism.
Eur J Endocrinol. 2013;168(4):557–64.
8. Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N,
Ganapathy K, Bhatti T, Stanley CA, Ganguly A. Genotype and phenotype
correlations in 417 children with congenital hyperinsulinism. J Clin
Endocrinol Metab. 2013;98(2):E355–63.
9. Arya VB, Guemes M, Nessa A, Alam S, Shah P, Gilbert C, Senniappan S,
Flanagan SE, Ellard S, Hussain K. Clinical and histological heterogeneity of
congenital hyperinsulinism due to paternally inherited heterozygous
ABCC8/KCNJ11 mutations. Eur J Endocrinol. 2014;171(6):685–95.
10. Banerjee I, Skae M, Flanagan SE, Rigby L, Patel L, Didi M, Blair J, Ehtisham S,
Ellard S, Cosgrove KE, et al. The contribution of rapid KATP channel gene
mutation analysis to the clinical management of children with congenital
hyperinsulinism. Eur J Endocrinol. 2011;164(5):733–40.
11. Kumaran A, Kapoor RR, Flanagan SE, Ellard S, Hussain K. Congenital
hyperinsulinism due to a compound heterozygous ABCC8 mutation with
spontaneous resolution at eight weeks. Horm Res Paediatr. 2010;73(4):287–92.
12. Welters A, Lerch C, Kummer S, Marquard J, Salgin B, Mayatepek E, Meissner
T. Long-term medical treatment in congenital hyperinsulinism: a descriptive
analysis in a large cohort of patients from different clinical centers.
Orphanet J Rare Dis. 2015;10:150.
13. Gong C, Huang S, Su C, Qi Z, Liu F, Wu D, Cao B, Gu Y, Li W, Liang X, et al.
Congenital hyperinsulinism in Chinese patients: 5-yr treatment outcome of 95
clinical cases with genetic analysis of 55 cases. Pediatr Diabetes. 2015;17(3):
227–34.
14. Demirbilek H, Shah P, Arya VB, Hinchey L, Flanagan SE, Ellard S, Hussain K.
Long-term follow-up of children with congenital hyperinsulinism on
octreotide therapy. J Clin Endocrinol Metab. 2014;99(10):3660–7.
15. Glaser B, Landaw H. Long-term treatment with the somatostatin analogue
SMS 201-995: alternative to pancreatectomy in persistent hyperinsulinaemic
hypoglycaemia of infancy. Digestion. 1990;45 Suppl 1:27–35.
16. Skae M, Avatapalle HB, Banerjee I, Rigby L, Vail A, Foster P, Charalambous C,
Bowden L, Padidela R, Patel L, et al. Reduced glycemic variability in
diazoxide-responsive children with congenital hyperinsulinism using
supplemental omega-3-polyunsaturated fatty acids; a pilot trial with
MaxEPA(R.). Front Endocrinol (Lausanne). 2014;5:31.
17. Han B, Newbould M, Batra G, Cheesman E, Craigie RJ, Mohamed Z, Rigby L,
Padidela R, Skae M, Mironov A, et al. Enhanced islet cell nucleomegaly
defines diffuse congenital hyperinsulinism in infancy but not other forms of
the disease. Am J Clin Pathol. 2016;145(6):757–68.
18. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross
sectional stature and weight reference curves for the UK, 1990. Arch Dis
Child. 1995;73(1):17–24.
19. Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J,
Vauhkonen I, Kere J, Laakso M, Ashcroft F, et al. Dominantly inherited
hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J
Clin Invest. 2000;106(7):897–906.
20. Yorifuji T, Hosokawa Y, Fujimaru R, Kawakita R, Doi H, Matsumoto T,
Nishibori H, Masue M. Lasting 18F-DOPA PET uptake after clinical remission
of the focal form of congenital hyperinsulinism. Horm Res Paediatr. 2011;
76(4):286–90.
21. Sogno Valin P, Proverbio MC, Diceglie C, Gessi A, di Candia S, Mariani B, Zamproni
I, Mangano E, Asselta R, Battaglia C, et al. Genetic analysis of Italian patients with
congenital hyperinsulinism of infancy. Horm Res Paediatr. 2013;79:236–42.
22. De Leon DD, Stanley CA. Mechanisms of disease: advances in diagnosis and
treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab.
2007;3(1):57–68.
23. Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J,
Brunelle F, Nihoul-Fekete C, Saudubray JM, et al. Glucose metabolism in 105
children and adolescents after pancreatectomy for congenital
hyperinsulinism. Diabetes Care. 2012;35(2):198–203.
24. Ismail D, Smith VV, de Lonlay P, Ribeiro MJ, Rahier J, Blankenstein O,
Flanagan SE, Bellanne-Chantelot C, Verkarre V, Aigrain Y, et al. Familial focal
congenital hyperinsulinism. J Clin Endocrinol Metab. 2010;96(1):24–8.
25. Russo L, Iafusco D, Brescianini S, Nocerino V, Bizzarri C, Toni S, Cerutti F,
Monciotti C, Pesavento R, Iughetti L, et al. Permanent diabetes during the
first year of life: multiple gene screening in 54 patients. Diabetologia. 2011;
54(7):1693–701.
26. Mohnike K, Wieland I, Barthlen W, Vogelgesang S, Empting S, Mohnike W,
Meissner T, Zenker M. Clinical and genetic evaluation of patients with KATP
channel mutations from the German registry for congenital hyperinsulinism.
Horm Res Paediatr. 2014;81(3):156–68.
27. Shimomura K, Flanagan SE, Zadek B, Lethby M, Zubcevic L, Girard CA, Petz
O, Mannikko R, Kapoor RR, Hussain K, et al. Adjacent mutations in the
gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. EMBO
Mol Med. 2009;1(3):166–77.
28. Bellanne-Chantelot C, Saint-Martin C, Ribeiro MJ, Vaury C, Verkarre V, Arnoux
JB, Valayannopoulos V, Gobrecht S, Sempoux C, Rahier J, et al. ABCC8 and
KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive
congenital hyperinsulinism. J Med Genet. 2010;47(11):752–9.
29. Ilamaran V, Venkatesh C, Manish K, Adhisivam B. Persistent hyperinsulinemic
hypoglycemia of infancy due to homozygous KCNJ11 (T294M) mutation.
Indian J Pediatr. 2010;77(7):803–4.
30. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-
sensitive potassium channels. Endocr Rev. 1999;20(2):101–35.
Salomon-Estebanez et al. Orphanet Journal of Rare Diseases  (2016) 11:163 Page 10 of 11
31. Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, Thornton P, Ganguly A,
Shyng SL, Stanley CA. Clinical characteristics and biochemical mechanisms
of congenital hyperinsulinism associated with dominant KATP channel
mutations. J Clin Invest. 2008;118(8):2877–86.
32. Park SE, Flanagan SE, Hussain K, Ellard S, Shin CH, Yang SW. Characterization
of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients
with congenital hyperinsulinism. Eur J Endocrinol. 2011;164(6):919–26.
33. Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, Harmer SC,
Shield JP, Tinker A, Ellard S, Hussain K. Hyperinsulinaemic hypoglycaemia
and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations.
Diabetologia. 2011;54(10):2575–83.
34. Christesen HT, Brusgaard K, Hussain K. Recurrent spontaneous hypoglycaemia
causes loss of neurogenic and neuroglycopaenic signs in infants with
congenital hyperinsulinism. Clin Endocrinol (Oxf). 2012;76(4):548–54.
35. Nestorowicz A, Glaser B, Wilson BA, Shyng SL, Nichols CG, Stanley CA,
Thornton PS, Permutt MA. Genetic heterogeneity in familial hyperinsulinism.
Hum Mol Genet. 1998;7(7):1119–28.
36. Shyng SL, Ferrigni T, Shepard JB, Nestorowicz A, Glaser B, Permutt MA,
Nichols CG. Functional analyses of novel mutations in the sulfonylurea
receptor 1 associated with persistent hyperinsulinemic hypoglycemia of
infancy. Diabetes. 1998;47(7):1145–51.
37. Powell PD, Bellanne-Chantelot C, Flanagan SE, Ellard S, Rooman R, Hussain
K, Skae M, Clayton P, de Lonlay P, Dunne MJ, et al. In vitro recovery of ATP-
sensitive potassium channels in beta-cells from patients with congenital
hyperinsulinism of infancy. Diabetes. 2011;60(4):1223–8.
38. Ohkubo K, Nagashima M, Naito Y, Taguchi T, Suita S, Okamoto N, Fujinaga H,
Tsumura K, Kikuchi K, Ono J. Genotypes of the pancreatic beta-cell K-ATP channel
and clinical phenotypes of Japanese patients with persistent hyperinsulinaemic
hypoglycaemia of infancy. Clin Endocrinol (Oxf). 2005;62(4):458–65.
39. Suchi M, MacMullen CM, Thornton PS, Adzick NS, Ganguly A, Ruchelli ED,
Stanley CA. Molecular and immunohistochemical analyses of the focal form
of congenital hyperinsulinism. Mod Pathol. 2006;19(1):122–9.
40. Hardy OT, Hernandez-Pampaloni M, Saffer JR, Suchi M, Ruchelli E, Zhuang H,
Ganguly A, Freifelder R, Adzick NS, Alavi A, et al. Diagnosis and localization
of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr.
2007;150(2):140–5.
41. Lee BH, Lee J, Kim JM, Kang M, Kim GH, Choi JH, Kim J, Kim CJ, Kim DY, Kim SC,
et al. Three novel pathogenic mutations in KATP channel genes and somatic
imprinting alterations of the 11p15 region in pancreatic tissue in patients with
congenital hyperinsulinism. Horm Res Paediatr. 2015;83(3):204–10.
42. Brunetti-Pierri N, Olutoye OO, Heptulla R, Tatevian N. Case report: pathological
features of aberrant pancreatic development in congenital hyperinsulinism
due to ABCC8 mutations. Ann Clin Lab Sci. 2008;38(4):386–9.
43. Coventry A, Bull-Otterson LM, Liu X, Clark AG, Maxwell TJ, Crosby J, Hixson
JE, Rea TJ, Muzny DM, Lewis LR, et al. Deep resequencing reveals excess
rare recent variants consistent with explosive population growth. Nat
Commun. 2010;1:131.
44. Arya VB, Aziz Q, Nessa A, Tinker A, Hussain K. Congenital hyperinsulinism:
clinical and molecular characterisation of compound heterozygous ABCC8
mutation responsive to Diazoxide therapy. Int J Pediatr Endocrinol. 2014;
2014(1):24.
45. Fernandez-Marmiesse A, Salas A, Vega A, Fernandez-Lorenzo JR, Barreiro J,
Carracedo A. Mutation spectra of ABCC8 gene in Spanish patients with
Hyperinsulinism of Infancy (HI). Hum Mutat. 2006;27(2):214.
46. Bennett JT, Vasta V, Zhang M, Narayanan J, Gerrits P, Hahn SH. Molecular
genetic testing of patients with monogenic diabetes and hyperinsulinism.
Mol Genet Metab. 2015;114(3):451–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Salomon-Estebanez et al. Orphanet Journal of Rare Diseases  (2016) 11:163 Page 11 of 11
